Stocks · Healthcare · Biotechnology
Stoke Therapeutics, Inc. STOK
$25.62 -1.50% Close, Oct 2, 2026 · NASDAQ · Market cap $1.65B
Next earnings report: Nov 3, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $-3.36, down 495.3% year over year.
- Revenue over the last four quarters was $27.6M, down 86.2% from a year earlier, slowing from -83.2% a quarter earlier.
- Operating margin narrowed to -809.7% from 20.2% a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
Growth12Very weak
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 6%
- EPS growth (TTM, YoY)Bottom 5%
- FCF growth (TTM, YoY)Bottom 2%
- Revenue growth, 3-year CAGRTop 5%
- Revenue growth accelerationBottom 32%
Quality19Very weak
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 19%
- Gross marginTop 25%
- Operating marginBottom 13%
- Accruals (lower is better)Top 45%
- Interest coverBottom 3%
Value29Very weak
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 41%
- Free-cash-flow yieldBottom 36%
- EBITDA / enterprise valueBottom 35%
- Sales / enterprise valueBottom 12%
Momentum33Weak
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 44%
- 6-month returnBottom 23%
- 1-year return vs S&P 500Bottom 47%
- Distance from 52-week highBottom 45%
- Trend checklist (0–4)Bottom 14%
Revisions26Very weak
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 23%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 43%
- Upside to consensus price targetTop 37%
Stability48Neutral
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 36%
- Maximum drawdown, 3 yearsTop 44%
- Beta vs S&P 500 (lower is better)Bottom 22%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -83.2% | -86.2% | ↓ |
| EPS growth (YoY) | -458.2% | -495.3% | ↓ |
| Gross margin | 100.0% | 84.7% | ↓ |
| Operating margin | 20.2% | -809.7% | ↓ |
| FCF margin | 30.6% | -654.9% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -86.2% | -83.2% | ↓ | Bottom 6% |
| EPS growth (TTM, YoY) | -495.3% | -458.2% | ↓ | Bottom 5% |
| Gross margin | 84.7% | 100.0% | ↓ | Top 25% |
| Operating margin | -809.7% | 20.2% | ↓ | Bottom 13% |
| Net margin | -753.6% | 26.3% | ↓ | — |
| Free-cash-flow margin | -654.9% | 30.6% | ↓ | — |
| Return on invested capital | -62.7% | — | Bottom 19% | |
| Revenue growth, 3-year CAGR | 145.9% | — | Top 5% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -7.6%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 106.6%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +523.7 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
- Interest cover (operating income / interest)How many times operating profit covers interest.
- -4856.0×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -10.99%
- Shareholder yield
- -10.99%
- Share count change, 1 year
- +13.1%
- Share count change, 3-year CAGR
- +14.3%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 3, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- -16.4%
- Average 2-day reaction, last 8
- -0.8%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $51.00
- Target vs current price
- +99.1%
- Analysts with a rating
- 16
- Share rating Buy or Strong Buy
- 81%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 3, 2026 | -17.0% | +2.4% | +13.3% | +9.6% | — |
| May 7, 2026 | +1.3% | -1.5% | -4.7% | -9.5% | -11.2% |
| Mar 16, 2026 | -29.3% | +2.3% | +1.0% | +5.6% | -11.5% |
| Nov 4, 2025 | -20.4% | -2.9% | -14.3% | +14.2% | +16.2% |
| Aug 12, 2025 | +29.8% | +2.8% | +40.7% | +67.7% | +92.6% |
| May 13, 2025 | +613.5% | -7.6% | +1.8% | +17.6% | +37.2% |
| Mar 18, 2025 | +64.7% | -1.4% | -7.9% | -16.0% | +27.8% |
| Nov 5, 2024 | +9.6% | -0.4% | +5.4% | -12.7% | -12.1% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 3, 2026 | -$0.93 | -$0.80 | -17.0% | $9.3M |
| May 7, 2026 | -$0.79 | -$0.80 | +1.3% | $6.2M |
| Mar 16, 2026 | -$0.97 | -$0.75 | -29.3% | $1.4M |
| Nov 4, 2025 | -$0.65 | -$0.54 | -20.4% | $10.6M |
| Aug 12, 2025 | -$0.40 | -$0.57 | +29.8% | $13.8M |
| May 13, 2025 | $1.90 | -$0.37 | +613.5% | $158.6M |
| Mar 18, 2025 | -$0.18 | -$0.51 | +64.7% | $22.6M |
| Nov 5, 2024 | -$0.47 | -$0.52 | +9.6% | $4.9M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 56.03× | — | — | Bottom 12% |
| Free-cash-flow yield | -10.93% | — | — | Bottom 36% |
| Earnings yield | -13.11% | — | — | Bottom 41% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -4.1%
- 200-day average slope (20 days)
- -0.9%
- Distance from 50-day average
- -14.3%
- Distance from 200-day average
- -19.1%
- RSI (14)
- 35.1
- Relative volume
- 0.90×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 47.5%
- Volatility vs own 5-year history
- 6th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 1.76
- Correlation with S&P 500
- 0.40
- Current drawdown from 1-year high
- -33.2%
- Maximum drawdown, 3 years
- -66.3%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Jan 19, 2021 | Oct 27, 2023 | -95.2% | 699 days | Not yet recovered |
| Nov 10, 2020 | Nov 19, 2020 | -12.4% | 7 days | 3 days (Nov 24, 2020) |
| Nov 30, 2020 | Dec 2, 2020 | -11.7% | 2 days | 8 days (Dec 14, 2020) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $1.65B
- EPS, diluted (TTM)
- -$3.36
- Revenue (TTM)
- $27.6M
- 52-week range
- $20.32 – $40.22
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $12.4M | $8.8M | $36.6M | $184.4M |
| Gross profit | $0 | $12.4M | $8.8M | $36.6M | $184.4M |
| Operating income | -$86.1M | -$104.4M | -$114.8M | -$101.4M | -$20.6M |
| Net income | -$85.8M | -$101.1M | -$104.7M | -$89.0M | -$6.9M |
| EPS (diluted) | -$2.34 | -$2.60 | -$2.38 | -$1.65 | -$0.12 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.9M | $22.6M | $158.6M | $13.8M | $10.6M | $1.4M | $6.2M | $9.3M |
| Net income | -$26.4M | -$10.5M | $112.9M | -$23.5M | -$38.3M | -$57.9M | -$50.0M | -$61.6M |
| EPS (diluted) | -$0.47 | -$0.18 | $1.90 | -$0.40 | -$0.65 | -$0.99 | -$0.79 | -$0.93 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$66.9M | -$31.9M | -$81.1M | -$86.9M | $45.6M |
| Capital expenditure | -$1.2M | -$4.0M | -$1.6M | -$203,000 | -$670,000 |
| Free cash flow | -$68.1M | -$35.8M | -$82.7M | -$87.1M | $44.9M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $1.3M | $45.3M | $52.1M | $128.8M | $97.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $292.8M
- Total assets
- $394.0M
- Total liabilities
- $48.4M
- Total debt
- $2.7M
- Net debt
- -$107.3M
- Shareholders’ equity
- $345.5M
As of Jun 30, 2026 (filed Aug 3, 2026).
Short interest
- Shares sold short
- 11,150,236
- Days to cover
- 17.31
- Change vs previous report
- -0.5%
FINRA short interest, settlement date Sep 15, 2026.